CYP17 Inhibitors for Prostate Cancer Treatment - An Update

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|15|9|868-899

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.15, Iss.9, 2008-04, pp. : 868-899

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design

By  

Letters in Drug Design & Discovery, Vol. 6, Iss. 5, 2009-07 ,pp. : 337-344

Bentham Science Publishers

Access to resources Recommend Favorite

Angiogenesis inhibitors in the treatment of prostate cancer

By Kluetz Paul G   Figg William D   Dahut William L  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 233-247

Informa Healthcare

Access to resources Recommend Favorite

Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17&bgr;- hydroxysteroid Dehydrogenase (17&bgr;-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer

By  

Letters in Drug Design & Discovery, Vol. 7, Iss. 9, 2010-11 ,pp. : 650-656

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of P450 17 as a New Strategy for the Treatment of Prostate Cancer

By  

Current Medicinal Chemistry, Vol. 12, Iss. 14, 2005-07 ,pp. : 1623-1629

Bentham Science Publishers

Access to resources Recommend Favorite

Synthesis and Biochemical Evaluation of a Range of 4-(n-alkanesulfonate) benzyl Imidazole-Based Compounds as Inhibitors of Rat Testicular 17-hydroxylase/17,20-lyase (P45017) in the Treatment of Hormone- Dependent Prostate Cancer

By  

Letters in Drug Design & Discovery, Vol. 11, Iss. 8, 2014-10 ,pp. : 1000-1009

Bentham Science Publishers

Access to resources Recommend Favorite